Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H22N2O8 |
Molecular Weight | 442.4187 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12[C@@H](O)[C@]3([H])C(=C)C4=CC=CC(O)=C4C(=O)C3=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C
InChI
InChIKey=MHIGBKBJSQVXNH-IWVLMIASSA-N
InChI=1S/C22H22N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-6,10,14-15,17,25,27-29,32H,1H2,2-3H3,(H2,23,31)/t10-,14-,15+,17+,22+/m1/s1
Molecular Formula | C22H22N2O8 |
Molecular Weight | 442.4187 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Methacycline is a tetracycline antibiotic. Similar to other tetracyclines, it has a wide spectrum of antimicrobial action. It is active against most Gram-positive bacteria (pneumococci, streptococci, staphylococci) and Gram-negative bacteria (E. coli, salmonella, shigella, etc.), and towards agents causing onithosis, psittacosis, trachoma, and some Protozoa. Like other tetracyclines, the general usefulness of methacycline has been reduced with the onset of bacterial resistance. Methacycline inhibits the binding of aminoacyl-tRNA to the mRNA-ribosome complex. Methacycline inhibits cell growth by inhibiting translation. It binds to the 16S part of the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. Methacycline is mostly used for the treatment of acute bacterial exacerbations of chronic bronchitis.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4199710/ |
200 mg 1 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
METHACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
47.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4199710/ |
200 mg 1 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
METHACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4199710/ |
200 mg 1 times / day multiple, intravenous dose: 200 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
METHACYCLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day steady, oral Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, adult n = 62 Health Status: unhealthy Condition: bronchitis Age Group: adult Sex: unknown Population Size: 62 Sources: |
Disc. AE: Gastrointestinal disorders... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (3 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Gastrointestinal disorders | 3 patients Disc. AE |
600 mg 1 times / day steady, oral Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: |
unhealthy, adult n = 62 Health Status: unhealthy Condition: bronchitis Age Group: adult Sex: unknown Population Size: 62 Sources: |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5111303
Methacycline inhibited Pseudomonas pseudomallei strains with MIC means ranged from 1.3 to 2.7 ug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:21:05 GMT 2023
by
admin
on
Fri Dec 15 17:21:05 GMT 2023
|
Record UNII |
IR235I7C5P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01AA05
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
||
|
NCI_THESAURUS |
C1595
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
||
|
WHO-ATC |
J01AA05
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D008690
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
IR235I7C5P
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
METACYCLINE
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
1727
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL249837
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
914-00-1
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
DTXSID2023272
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
1330
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
m7285
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
213-017-5
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
DB00931
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
100000088208
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
SUB08801MIG
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
C61839
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
6805
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | |||
|
6812
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY | RxNorm | ||
|
3118
Created by
admin on Fri Dec 15 17:21:05 GMT 2023 , Edited by admin on Fri Dec 15 17:21:05 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |